Relapse-specific therapeutic vulnerability evaluation in childhood and young adult ALL (REVEALL)

Survival for children and young people with acute lymphoblastic leukaemia (ALL) is high, but in those where the disease comes back after treatment, the prognosis isn’t as good. Developing new treatments for relapsed ALL is notoriously difficult, mainly because relapse is rare. This means that patients are missing out on effective treatments due to a lack of information to guide their therapy. Dr Marc Mansour and his team aim to address this problem by establishing a nationwide study analysing patient samples and uncovering the cancer’s genetics to guide which treatments the patients receive, giving them the best chance of survival.

This project is co-funded with Cancer Research UK as part of the Cancer Research UK–Children with Cancer UK Innovation Awards. Children with Cancer UK has contributed £483,311.35 towards this research project, the total cost of the project is £966,622.70

Project Details

  • Project Title

    Improving outcomes for children whose leukaemia relapses after treatment

  • Lead Researcher

    Dr David O’Connor, Professor Marc Mansour and Dr Jack Bartram

  • Research Centre

    University College London Cancer Institute and Great Ormond Street Institute of Child Health

  • City & Institution Postcode

    London, WC1E 6BT

  • Start Date

    --

  • Duration

    36 months

  • Grant Amount

    £966,622.70

Marc Mansour team

Overview

Survival for children and young people with the blood cancer acute lymphoblastic leukaemia (ALL) is high, but in those where the disease comes back after treatment, the prognosis isn’t as good. Developing new, targeted treatments for relapsed ALL is notoriously difficult, mainly because relapse is rare, so conducting studies that yield significant results can be challenging. This means that children with the disease are missing out on effective treatments due to a lack of information to guide their therapy.

Dr David O’Connor, Professor Marc Mansour and Dr Jack Bartram have formed a team to address this problem by establishing a nationwide study analysing patient samples and uncovering the cancer’s genetics and sensitivities to different treatments. This form of personalised medicine will guide which treatments the patients receive, giving them the best chance of survival. In addition, the team hope to use the samples to identify predictive indicators of cancer, commonly called biomarkers. This will help identify future children and young people with ALL who are at higher risk of relapse, while also potentially uncovering new targets for future treatments for ALL.

Potential impact

A quarter of all childhood deaths are from leukaemia, which is predominantly due to relapses. This study has the potential to make a significant change to the overall survival of children and young people with cancer.

About the research team

Professor Marc Mansour is an honorary consultant haematologist at UCLH and Professor at University College London Cancer Institute/Institute of Child Health Great Ormond Street. His research focuses on understanding the biology of blood cancers.

Dr David O’Connor is a consultant paediatric haematologist at Great Ormond Street Hospital and is responsible for the daily care of children with diseases of the blood. His research focuses on understanding chemotherapy responses in children with leukaemia.

Dr Jack Bartram is a consultant paediatric haematologist at Great Ormond Street Hospital and leads on molecular diagnostics.

Professor Owen Williams is a Professor of Cancer Biology at Institute of Child Health Great Ormond Street and leads on studies in mice.

Animal research:

The research project involves the use of mice in experiments.

Newsletter icon
Newsletter icon

Sign up to our e-newsletter today

Sign up to our e-newsletter and receive exclusive stories straight to your inbox. You will also find out about our latest childhood cancer research news along with updates on our fundraising events, charity news and opportunities to support us. Don’t miss out!

By signing up to this newsletter I agree to receive general and financial appeal emails from Children with Cancer UK